Brief: Shenzhen Hepalink Pharmaceutical Posts FY Revenue RMB6.42 Billion
30/03/2022 14:22
March 30 (Reuters) - Shenzhen Hepalink Pharmaceutical:
* FY REVENUE RMB6.42 BILLION VERSUS RMB5.32 BILLION
* FY PROFIT ATTRIBUTABLE RMB382.6 MILLION VERSUS RMB1.02
BILLION
* EASING TREND OF RAW MATERIAL PRICES SINCE Q3 2021 WILL
HAVE
POSITIVE IMPACT ON EARNINGS, GROSS MARGIN IN 2022
Source text for Eikon: ID:nHKS1x4lmG
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA